- Home
- ENTA
as 12-20-2024 4:00pm EST
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 127.8M | IPO Year: | 2013 |
| Target Price: | $19.50 | AVG Volume (30 days): | 537.1K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.48 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.70 - $17.80 | Next Earning Date: | 02-05-2025 |
| Revenue: | $67,635,000 | Revenue Growth: | -14.61% |
| Revenue Growth (this year): | 11.8% | Revenue Growth (next year): | 3.99% |
Stock Insider Trading Activity of Enanta Pharmaceuticals Inc. (ENTA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Luu Brendan | ENTA | Chief Business Officer | Dec 6 '24 | Sell | $8.06 | 2,283 | $18,400.98 | 36,047 | |
| Kieffer Tara Lynn | ENTA | Chief Product Strategy Officer | Dec 6 '24 | Sell | $8.06 | 2,283 | $18,400.98 | 29,305 | |
| Rottinghaus Scott T. | ENTA | Chief Medical Officer | Dec 6 '24 | Sell | $8.06 | 866 | $6,979.96 | 17,918 | |
| Luly Jay R. | ENTA | President and CEO | Dec 6 '24 | Sell | $8.06 | 5,142 | $41,444.52 | 801,638 | |
| MELLETT PAUL J | ENTA | Chief Fin. & Admin Officer | Dec 6 '24 | Sell | $8.06 | 2,591 | $20,883.46 | 91,710 | |
| Or Yat Sun | ENTA | Chief Scientific Officer | Dec 6 '24 | Sell | $8.06 | 2,591 | $20,883.46 | 369,109 |
Latest Enanta Pharmaceuticals Inc. News
ENTA Breaking Stock News: Dive into ENTA Ticker-Specific Updates for Smart Investing
Clinical Trials Arena
11 days ago
Enanta’s zelicapavir shows promise in paediatric respiratory syncytial virus trial
MT Newswires
13 days ago
Enanta Pharma Reports Positive Phase 2 Results for Zelicapavir as Treatment of Respiratory Syncytial Virus
Business Wire
13 days ago
Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)
Business Wire
15 days ago
Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)
TipRanks
23 days ago
Enanta Pharmaceuticals’ Reduced Reporting: Potential Impact on Investor Appeal and Stock Volatility
MT Newswires
25 days ago
Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $14 From $16, Maintains Perform Rating
MT Newswires
a month ago
Enanta Pharmaceuticals Fiscal Q4 Net Loss Widens, Revenue Declines
Zacks
a month ago
Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue Estimates
Compare ENTA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ENTA Enanta Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.